China Health Market Update Issue 1 ▏ November 26, 2013
China Health Market Update Content Hot Issues…………………………………..3 M&As………………………………………..4 Investment & Cooperation………………..5 Product R&D……………………………….6 Data & Facts………………………………..7
China Health Market Update Hot Issues Merck to invest € 80 million in Nantong, China with New Pharmaceutical Manufacturing Facility The new facility will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck's leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively. Weblink Johnson&Johnson to reinvest $1 billion to save ill-performed Xian Janssen Pharma After core business OTC drug department being designated to Shanghai Johnson& Johnson, Xian Janssen Pharma has experience overall low sales performance since its establishment 25 years ago. Weblink Wanzhou District to strenghen its bio-tech competence with RMB 3 billion Located in Chongqing Special District and near the Three-gorge area, Wanzhou District intend to invest RMB 300 million in 5 years to build its bio-tech industry. Weblink
China Health Market Update M&As Time Acquired firm Acquiring firm Amount involved Remark 2013.11.12 ViroPharma Shire PLC USD4.2 billion To strengthen its portfolio of lucrative drugs to treat rare disease 2013.11.12 Ningbo Promise, Shandong Walvax Undisclosed Shijie Biopharm, Putian Biotechnology Shengtai 2013.11.13 Ningbo Yongxin Medical China David Medical RMB4.4 million Set foot in infusion pump field 2013.11.18 Medica (France) Korian (France) USD1.5 billion To become the largest aged service operator in Europe 2013.11.18 Shanghai Jianzhong Tofflon (300171) RMB 40 million Medical Packaging Co. 2013.11.18 Shanghai Dianfan Medical Tofflon (300171) RMB35 million Tech Co. 2013.11.18 Jiangsu Aidier Medical Shanghai Kinetic Medical RMB528 million To extend to orthopedic device segments
China Health Market Update Investment & Cooperation Time Invitee Initiator Amount Remark 2013.11.14 Immatics (Germany) Roche USD1 billion To develop cancer vaccines and other immunotherapies 2013.11.14 BeiGene Merck Serono USD200 million Cancer drugs 2013.11.14 Xi’an Johnson&Johnson USD 300 million To build the largest vaccine base in Asia 2013.11.15 Yangpu District healthcare DaVita Healthcare To form a Renal authorities of Shanghai Partners Inc. Dialysis Technology Collaboration Base 2013.11.18 Fuzhou Dongze Medical Blue Sail (Shanghai) RMB30 million Blood purification Device Assets Management business
China Health Market Update Products R&D Time Product Company Status Remark 2013.11.12 Unknown Boehringer-Ingelheim and Succeed in R&D Prevention of Eli Lilly hypoglycemia, cardiovascular and weight gain 2013.11.18 ibrutinib JNJ and Pharmacyclics Approved by FDA Luekemia drug 2013.11.18 Xofigo Bayer Approved by EC CRPC disease treatment 2013.11.20 Xeljanz Pfizer Approved by FDA RA treatment 2013.11.20 Vitekta Gilead Approved by EC certain HIV treatment regimens
China Health Market Update Data & Facts
China Health Market Update Data & Facts In looking at just the M&A activity in the top seven sectors, the trends are easier to discern (Figure 3). In 2012, the only sector with any increase in deal volume was devices.
China Health Market Update About ResearchInChina ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intel igence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research. Our Major Activities Multi-users market reports Database-RICDB Custom Research Company Search RICDB (http://www.researchinchina.com/data/database.html ), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.
For any questions about this, please do not hesitate to contact us at Address: Room 502, Unit 3, Block 3, Tower C, Changyuan Tiandi Bldg, Suzhou Street, Haidian District, Beijing, 100080 Tel: 86-10-82600828 Fax: 86-10-82601570